FasL-engineered biomaterials with immunomodulatory function
AssigneesUniversity of Louisville Research Foundation, Inc., Georgia Tech Research Corporation
InventorsHaval Shirwan, Andres J. Garcia, Esma S. Yolcu, Hong Zhao, Devon Headen
Life of this patent
Estimating the term…
Abstract
Described herein are FasL-engineered biomaterials, as well as methods of making and using such FasL-engineered biomaterials, such as for immunomodulation, such as for inducing immunosuppression and specific immune tolerance, such as for preventing or reducing the risks of rejection of cellular or tissue grafts and/or the treatment of autoimmune disorders such as Type I diabetes. In specific embodiments, the FasL-engineered biomaterials are biotinylated microgels bound to SA-FasL.
Claims20
A biomaterial comprising:
- a) a hydrogel comprising maleimide-terminated four-arm polyethylene glycol (PEG-4MAL);
- b) a biotin moiety displayed on the hydrogel;
- and
- c) a chimeric FasL protein comprising a FasL moiety and a streptavidin moiety conjugated to the hydrogel via the biotin moiety;
- wherein,
- the FasL moiety comprises an extracellular domain that lacks matrix metalloproteinase sensitive sites.
A method of making a biomaterial displaying a fusion protein comprising streptavidin and a FasL moiety, the method comprising reacting biotin-PEG-thiol with PEG-4MAL macromere to generate a microgel crosslinked with dithiothreitol (DTT) via microfluidics polymerization and capturing a chimeric protein comprising streptavidin and a FasL moiety via the biotin.
A biomaterial displaying a fusion protein comprising streptavidin and a FasL moiety produced by a method comprising reacting biotin-PEG-thiol with PEG-4MAL macromere to generate a microgel crosslinked with dithiothreitol (DTT) via microfluidics polymerization and capturing a chimeric protein comprising streptavidin and a FasL moiety via the biotin, wherein the microgel has a 150 μm diameter.
Dependencies are inferred from the claim text.